Literature DB >> 22020338

Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells.

E Diaz-Rodriguez1, M García-Lavandeira, S Perez-Romero, A Senra, C Cañibano, I Palmero, M G Borrello, C Dieguez, C V Alvarez.   

Abstract

Somatotrophs produce growth hormone (GH) and are the most abundant secretory cells of the pituitary. Somatotrophs express the transcription factor Pit-1 and the dependence receptor RET, its co-receptor GFRa1 and ligand GDNF. Pit-1 is a transcription factor essential for somatotroph proliferation and differentiation and for GH expression. GDNF represses excess Pit-1 expression preventing excess GH. In the absence of GDNF, RET behaves as a dependence receptor, becomes intracellularly processed and induces strong Pit-1 expression leading to p53 accumulation and apoptosis. How accumulation of Pit-1 leads to p53 expression is unknown. We have unveiled the relationship of Pit-1 with the p19Arf gene. There is a parallel correlation of RET processing, Pit-1 increase and ARF protein and mRNA expression. Interfering the pathway with RET, Pit-1 or p19Arf siRNA blocked apoptosis. We have found a Pit-1 DNA-binding element within the ARF promoter. Pit-1 directly regulates the CDKN2A locus and binds to the p19Arft promoter inducing p19Arf gene expression. The Pit-1-binding element is conserved in rodents and humans. RET/Pit-1 induces p19Arf/p53 and apoptosis not only in a somatotroph cell line but also in primary cultures of pituitary somatotrophs, where ARF siRNA interference also blocks p53 and apoptosis. Analyses of the somatotrophs in whole pituitaries supported the above findings. Thus Pit-1, a differentiation factor, activates the oncogene-induced apoptosis (OIA) pathway as oncogenes exerting a tight control in somatotrophs to prevent the disease due to excess of GH (insulin-resistance, metabolic disease, acromegaly).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020338     DOI: 10.1038/onc.2011.458

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.

Authors:  Muriel X G Draht; Kim M Smits; Benjamin Tournier; Valerie Jooste; Caroline Chapusot; Beatriz Carvalho; Arjen H G Cleven; Sarah Derks; Kim A D Wouters; Eric J T Belt; Hein B A C Stockmann; Herman Bril; Matty P Weijenberg; Piet A van den Brandt; Adriaan P de Bruïne; James G Herman; Gerrit A Meijer; Françoise Piard; Veerle Melotte; Manon van Engeland
Journal:  Mol Oncol       Date:  2014-02-02       Impact factor: 6.603

Review 2.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 3.  Regulation of pituitary stem cells by epithelial to mesenchymal transition events and signaling pathways.

Authors:  Leonard Y M Cheung; Shannon W Davis; Michelle L Brinkmeier; Sally A Camper; María Inés Pérez-Millán
Journal:  Mol Cell Endocrinol       Date:  2016-09-17       Impact factor: 4.102

4.  Correlation between multiple RET mutations and severity of Hirschsprung's disease.

Authors:  Kunihiro Ishii; Takashi Doi; Ken Inoue; Manabu Okawada; Geoffrey J Lane; Atsuyuki Yamataka; Chihiro Akazawa
Journal:  Pediatr Surg Int       Date:  2013-02       Impact factor: 1.827

5.  RET is a potential tumor suppressor gene in colorectal cancer.

Authors:  Y Luo; K D Tsuchiya; D Il Park; R Fausel; S Kanngurn; P Welcsh; S Dzieciatkowski; J Wang; W M Grady
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

6.  Dose-dependent dual role of PIT-1 (POU1F1) in somatolactotroph cell proliferation and apoptosis.

Authors:  Nicolas Jullien; Catherine Roche; Thierry Brue; Dominique Figarella-Branger; Thomas Graillon; Anne Barlier; Jean-Paul Herman
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

7.  The syndrome of central hypothyroidism and macroorchidism: IGSF1 controls TRHR and FSHB expression by differential modulation of pituitary TGFβ and Activin pathways.

Authors:  Marta García; Raquel Barrio; Montserrat García-Lavandeira; Angela R Garcia-Rendueles; Adela Escudero; Esther Díaz-Rodríguez; Darya Gorbenko Del Blanco; Ana Fernández; Yolanda B de Rijke; Elena Vallespín; Julián Nevado; Pablo Lapunzina; Vilborg Matre; Patricia M Hinkle; Anita C S Hokken-Koelega; María P de Miguel; José Manuel Cameselle-Teijeiro; Manuel Nistal; Clara V Alvarez; José C Moreno
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

8.  GFRα 1-2-3-4 co-receptors for RET Are co-expressed in Pituitary Stem Cells but Individually Retained in Some Adenopituitary Cells.

Authors:  Alberto Pradilla Dieste; Miguel Chenlo; Sihara Perez-Romero; Ángela R Garcia-Rendueles; Maria Suarez-Fariña; Montserrat Garcia-Lavandeira; Ignacio Bernabeu; José Manuel Cameselle-Teijeiro; Clara V Alvarez
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-24       Impact factor: 5.555

9.  The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.

Authors:  Salma Siddiqui; Stephen J Libertini; Christopher A Lucas; Alan P Lombard; Han Bit Baek; Rachel M Nakagawa; Kristine S Nishida; Thomas M Steele; Frank U Melgoza; Alexander D Borowsky; Blythe P Durbin-Johnson; LiHong Qi; Paramita M Ghosh; Maria Mudryj
Journal:  Cancer Lett       Date:  2020-04-21       Impact factor: 8.679

Review 10.  Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.

Authors:  Federica Barbieri; Stefano Thellung; Roberto Würth; Federico Gatto; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Manuela Albertelli; Diego Ferone; Tullio Florio
Journal:  Int J Endocrinol       Date:  2014-11-17       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.